|
|
||||||||



* Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London, United Kingdom;
Kennedy Institute, Imperial College, London, United Kingdom; and
Gene Targeting Unit, Department of Cellular and Molecular Neuroscience, Imperial College, Charing Cross Hospital, London, United Kingdom
The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output. Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.
This article has been cited by other articles:
![]() |
S. M. Eaton, A. C. Maue, S. L. Swain, and L. Haynes Bone Marrow Precursor Cells from Aged Mice Generate CD4 T Cells That Function Well in Primary and Memory Responses J. Immunol., October 1, 2008; 181(7): 4825 - 4831. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |